DelveInsight’s “Acral Lentiginous Melanoma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Acral lentiginous melanoma, historical and forecasted epidemiology as well as the Acral lentiginous melanoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

DelveInsight’s “Acral Lentiginous Melanoma Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the Acral Lentiginous Melanoma, epidemiology insights, Acral Lentiginous Melanoma market trends, therapies, and key companies working in the Acral Lentiginous Melanoma Market in the 7MM.

Acral Lentiginous Melanoma Overview

Acral lentiginous melanoma is an aggressive type of skin cancer. Melanoma is a group of serious skin cancers that arise from pigment cells (melanocytes); acral lentiginous melanoma is a kind of lentiginous skin melanoma. Acral lentiginous melanoma is the most common subtype in people with darker skin and is rare in people with lighter skin types. It is not caused by exposure to sunlight or UV radiation, and wearing sunscreen does not protect against it. 

Acral Lentiginous Melanoma Epidemiology Insights

• Acral lentiginous melanoma (ALM) is a subtype of melanoma predominantly occurring on palmar, plantar, and subungual skin. Though only accounting for 2–3% of all melanomas, ALM disproportionately affects African American, Hispanic, and Asian populations.

• The age-adjusted incidence rate of ALM overall was 1.8 per million person-years. The proportion of ALM among all melanoma subtypes was greatest in blacks (36%).

Click here to learn more about the Acral Lentiginous Melanoma Market Landscape

The Report Covers the Acral Lentiginous Melanoma Epidemiology Segmented by:

• Acral Lentiginous Melanoma are prevalent cases 

• Acral Lentiginous Melanoma diagnosed cases 

• Acral Lentiginous Melanoma treatment cases 

• Acral Lentiginous Melanoma incident cases 

Acral Lentiginous Melanoma Market Outlook

The Acral lentiginous melanoma market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Acral lentiginous melanoma market trends by analyzing the impact of current Acral lentiginous melanoma therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Acral lentiginous melanoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Acral lentiginous melanoma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Acral lentiginous melanoma market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Companies Working in the Acral Lentiginous Melanoma Market:

• AstraZeneca 

• Immunocore Ltd 

• Tizona Therapeutics 

• Bristol Myers Squibb 

• Atreca Inc 

And many others 

Acral Lentiginous Melanoma Therapies Covered and Analyzed in the Report:

• IBI308

• MGD013

• Sunitinib

• Nivolumab

• Ipilimumab

And many others 

 

Learn more about the Key Companies and Emerging Therapies in the Acral Lentiginous Melanoma Market

Table of Contents 

1. Key Insights 

2. Acral Lentiginous Melanoma  Introduction 

3. Executive Summary of Acral Lentiginous Melanoma         

4. Disease Background and Overview

5. Epidemiology and patient population

6. Acral Lentiginous Melanoma Emerging Therapies

7. Acral Lentiginous Melanoma Market Outlook

8. Market Access and Reimbursement of Therapies

9. Acral Lentiginous Melanoma Market Drivers 

10. Acral Lentiginous Melanoma Market Barriers 

11. Appendix

12. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

Learn about the detailed offerings of the report @ Acral Lentiginous Melanoma Market Outlook